PRAGMATIC STUDY ON THE USE OF 68GA-DOTA-TATE PET/CT IMAGING AS A STANDARD OF CARE TO INFLUENCE CLINICAL MANAGEMENT

Registry ID

CIMS-2019-02

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CIUSSS DE L'ESTRIE - CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE

Start date

2023-09-25

Last update

2020-01-06

Conditions

• SOMATOSTATIN RECEPTOR POSITIVE TUMOURS

Related clinical trials

• A PHASE I/II STUDY OF GALLIUM-68 HA-DOTATATE (68GA-HA-DOTATATE) IN PATIENTS WITH KNOWN OR SUSPECTED SOMATOSTATIN RECEPTOR POSITIVE TUMOURS
• A MULTICENTER OPEN-LABEL STUDY TO EVALUATE SAFETY AND DOSIMETRY OF LUTATHERA IN ADOLESCENT PATIENTS WITH SOMATOSTATIN RECEPTOR POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE (GEP-NET) TUMORS, PHEOCHROMOCYTOMA AND PARAGANGLIOMAS
• 68GA-HA-DOTATATE IMAGING OF SUSPECTED SOMATOSTATIN RECEPTOR POSITIVE TUMORS
• PHASE II STUDY TO MEASURE THE SAFETY OF 68GA-DOTA-TATE PET/CT IN THE DIAGNOSIS OF TUMORS EXPRESSING SOMATOSTATIN RECEPTORS
• AN OPEN LABEL PHASE II REGISTRY STUDY OF LUTETIUM-177 DOTA-TATE TREATMENT IN PATIENTS WITH SOMATOSTATIN POSITIVE TUMOURS
• "AN OPEN-LABEL PHASE II, REGISTRY STUDY OF LUTETIUM-177 [DOTA0, TYR3] OCTREOTATE (LU-DOTA-TATE) TREATMENT IN SUBJECTS WITH SOMATOSTATIN RECEPTOR POSITIVE TUMOURS."

View on source registry